REG - Retroscreen Vlgy Grp - Board Changes <Origin Href="QuoteRef">RVG.L</Origin>

hVIVOAnnouncement

06/09/2014 02:15

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140612:nRSL4229Ja


RNS Number : 4229J
Retroscreen Virology Group PLC
12 June 2014 
 
For immediate release 07.00: 12 June 2014 
 
RETROSCREEN VIROLOGY GROUP PLC 
 
("Retroscreen" or the "Company") 
 
BOARD CHANGES 
 
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human
challenge models of disease, is pleased to announce further strategic changes
to its Board of Directors ("Board") as part of the Company's ambitious growth
strategy.  Jaime Ellertson has been appointed as Non-Executive Chairman, with
immediate effect, succeeding David Norwood, who will continue to play a
pivotal role on the Board as a Non-Executive Director. 
 
Jaime Ellertson (55) has a strong track record of leading fast growing, data
and service driven companies through phases of rapid expansion, both in the
private and public arena.  Jaime is currently Chairman and Chief Executive
Officer of Everbridge Inc., a provider of multidimensional critical
communications solutions to leading Health Care, Corporate and Government
organisations globally.  He lives in Massachusetts and is a citizen of the
United States of America. 
 
Jaime previously served as the Chief Executive Officer, President and Director
of Gomez Inc. a company specialising in monitoring and managing Web site data
and Web application performance.  During his tenure he led Gomez Inc. through
an IPO registration that resulted in the successful sale of the company for
$295M to Compuware Corporation (NASDAQ: CPWR).  He served as Chief Executive
Officer, President and Director of S1 Corporation Inc. (NASDAQ: SONE), a
software provider to the financial services marketplace. Jaime also
orchestrated the highly successful turnaround of Interleaf, Inc. (NASDAQ:
LEAF), a provider of software tools for e-content management, culminating in
its acquisition for $852M by BroadVision Inc in 2000.  Earlier in his career,
Jaime founded several high growth software companies including Openware
Technologies Inc., Document Automation Corporation and Purview Technologies
Inc..  He has also served on the boards of a number of public and private US
and UK based companies including those indicated below. 
 
David Norwood was appointed Chairman of Retroscreen Virology Limited in
February 2011 and became Chairman of the Company in April 2012.  David remains
as a Non-Executive Director of the Company, with a focus on the Company's
business growth and investor strategy. 
 
Kym Denny, Chief Executive Officer, commented, "Retroscreen is expanding the
application of its hVIVO platform to address key bottlenecks in the
pharmaceutical industry.  I would like to welcome Jaime Ellertson as our new
Chairman, with his invaluable experience of developing companies with novel
ground breaking technologies into world leaders.  I would like to thank Dave
for guiding Retroscreen through its dramatic growth journey and I am delighted
that he will continue to serve on the Board.  I am excited to work with our
newly shaped Board to deliver our broader vision on a truly global scale." 
 
Mr Ellertson is a director/ partner or has been a director/ partner of the
following companies/ partnerships during the previous five years: 
 
Current 
 
Calliope Corporation 
 
Everbridge Europe Ltd. 
 
Everbridge Inc. 
 
Imodus Ltd. 
 
MicroTech Ltd. 
 
Peoplefluent Inc. 
 
PJE Vero LLC. 
 
Qvidian Corporation (previously Kadient Inc.) 
 
Vocal Continuity Solutions Ltd. 
 
Vocal Ltd. 
 
Vocal Mobile Solutions Ltd. 
 
Previous 
 
Cloudfloor Corporation (acquired by Everbridge March 2011) 
 
Danka Business Systems PLC 
 
Gomez Europe Ltd. 
 
Gomez Inc. 
 
Yankee Group Research Inc. 
 
Mr Ellertson does not hold any ordinary shares in the Company. 
 
Save for the information disclosed above there is no other information to be
disclosed on Mr Ellertson under Schedule 2(g) of the AIM Rules. 
 
For further information please contact: 
 
Retroscreen Virology Group plc                                                
        +44 207 756 1300 
 
Kym Denny (CEO) 
 
Graham Yeatman (FD) 
 
Numis Securities Limited                                                      
            +44 207 260 1000 
 
Michael Meade / Freddie Barnfield (Nominated Adviser) 
 
James Black / Michael Burke (Corporate Broking) 
 
Notes to Editors: 
 
Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life
sciences company pioneering a technology platform called hVIVO which uses
human models of disease involving healthy volunteers to study new drugs and
investigate disease in a safe, controlled environment. 
 
Retroscreen has established itself as the world leader in this field through
the provision of clinical services to third party study sponsors.  To date,
the Company has conducted over 35 clinical studies, involving more than 1600
volunteers for a range of leading industry, governmental and academic
clients. 
 
However, Retroscreen's hVIVO platform has a much wider application in helping
to understand illness better because the Company believes that the best way to
understand human disease is by studying it in humans, not laboratory models. 
 
This information is provided by RNS
The company news service from the London Stock Exchange